肝癌患者血清p16甲基化检测
被引量:2
肝癌患者血清p16甲基化检测
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2004年第9期569-570,共2页
Chinese Journal of Oncology
基金
陕西省科技攻关资助项目 ( 2 0 0 2K10 G1)
二级参考文献8
-
1Herman JG,Graff JR,Myohanen S,et al.Methylaiton-Specific PCR: a novel PCR assay for methylation status of CpG islands[].Proceedings of the National Academy of Sciences of the United States of America.1996
-
2Jahr S,Hentze H,Englisch S,et al.DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells[].Cancer Research.2001
-
3Anker P,Lefort F,Vasioukhin V,et al.K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer[].Gastroenterology.1997
-
4Mulcahy HE,Lyautey J,Lederrey C,et al.A prospective study of K-ras mutations in the plasma of pancreatic cancer patients[].Clinical Cancer Research.1998
-
5Wong IH,Lo YM,Zhang J,et al.Detection of aberrant p16 methylation in the plasma and serum of liver cancer pa-tients[].Cancer Research.1999
-
6Silva JM,Dominguez G,Villanueva MJ,et al.Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients[].British Journal of Cancer.1999
-
7Esteller M,Sanchez-Cespedes M,Rosell R, et al.Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients[].Cancer Research.1999
-
8Sanchez-Cespedes M,Esteller M,Wu L,et al.Gene promoter hypermethylation in tumors and serum of head and neck cancer patients[].Cancer Research.2000
共引文献30
-
1邓水秋,欧阳学农,余宗阳,房文铮,王文武,刘志臻.晚期非小细胞肺癌血清游离DNA水平变化及意义[J].山东医药,2013,53(30):6-8. 被引量:4
-
2汪洋,邹丽娟,许冠东,宫琳琳,周小棉,邵淑娟.微流控芯片检测肺癌患者血浆中p16基因异常甲基化在临床应用的评价[J].生物化学与生物物理进展,2004,31(12):1085-1090. 被引量:7
-
3冯毅,梁小波,刘永.CDKN2/p16甲基化的研究与结直肠癌[J].肿瘤研究与临床,2005,17(2):142-144.
-
4梁小波,刘永锠,孙俊宁,冯毅.结直肠癌患者cdkn2/p16基因异常的检测及临床意义[J].中华检验医学杂志,2005,28(5):497-498.
-
5姚群峰,康新江,郝巧玲,曾卫,周宜开.巢式甲基化特异性PCR检测食管癌病人血清中p16基因启动子区过甲基化[J].肿瘤防治研究,2005,32(8):463-466. 被引量:5
-
6赵中海,耿小平,朱立新,李晓明,刘宗石.肝细胞癌组织中RAS相关区域家族蛋白1A、肿瘤高甲基化基因1和P73基因的异常甲基化[J].中华外科杂志,2005,43(23):1528-1532. 被引量:6
-
7粱小波,刘永錩,孙俊宁,冯毅.结直肠癌患者血清中CDKN2/P16基因异常的检测(英文)[J].The Chinese-German Journal of Clinical Oncology,2005,4(6):361-364. 被引量:1
-
8朱斌,陈尔齐,楚建军,鹿亚超.大肠癌患者TPEF基因甲基化状态分析[J].江苏医药,2006,32(1):7-8. 被引量:1
-
9梁小波,刘永锠,孙俊宁,冯毅.结直肠癌患者血清中CDKN2/p16基因异常的检测[J].肿瘤研究与临床,2006,18(1):11-13.
-
10鹿亚超,楚建军,许示心,姜海燕,朱斌.血浆卵泡抑素结构域跨膜蛋白基因甲基化异常在大肠癌诊断中的价值[J].中华检验医学杂志,2006,29(2):143-144. 被引量:2
同被引文献20
-
1刘建余,覃扬,孙芝琳,孙泽芳.人原发性肝癌中p16,p15基因CpG岛甲基化研究[J].四川大学学报(自然科学版),2002,39(S1):127-132. 被引量:5
-
2Di Vinci A, Perdelli L, Banelli B, et al. p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer, 2005, 114: 414-421.
-
3Ranger GS, Jewell A, Thomas V, et al. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J Surg Oncol, 2004,88: 100-103.
-
4Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer, 2004, 4:428-433.
-
5Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res,2002, 62: 632-635.
-
6Davies G, Salter J, Hills M, et al. Conelation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res, 2003, 9: 2651-2656.
-
7Half E, Tang XM, Gwyn K, et al. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res, 2002, 62: 1676-1681.
-
8Stott FJ,Bates S,James MC,et al.The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2[].EMBO Journal.1998
-
9Tao W,Levine A J.P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2[].Proceedings of the National Academy of Sciences of the United States of America.1999
-
10Esteller M,Cordon-Cardo C,Corn PG,et al.p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2[].Cancer Research.2001
引证文献2
-
1吴飞翔,赵荫农.肝细胞癌中抑癌基因CDKN2A甲基化的研究进展[J].中国医学文摘(肿瘤学),2005,19(3):224-225.
-
2左文述,魏玲,王兴武,王永胜,于志勇,毕晔,刘岩松,周正波.浸润性乳腺癌组织MTS1和COX-2基因表达的临床意义[J].中华肿瘤杂志,2006,28(7):515-517. 被引量:7
二级引证文献7
-
1徐维华,汪立鑫.环氧合酶-2与乳腺癌的研究进展[J].中国现代药物应用,2009,3(3):180-181. 被引量:1
-
2罗春芳,朱润庆,王晖,芦玉兰.环氧合酶-2和基质金属蛋白酶-9在宫颈癌中的表达及其临床意义[J].中华肿瘤杂志,2007,29(7):526-530. 被引量:7
-
3郑刚,魏玲,左文述.抑癌基因与乳腺癌的研究进展[J].中华肿瘤防治杂志,2007,14(17):1350-1353. 被引量:2
-
4宋艳清,胡群,潘华雄,刘爱国,张柳清,张小玲,胡迎,陶红芳.急性白血病患儿骨髓细胞环氧合酶-2和survivin表达及其意义[J].实用儿科临床杂志,2007,22(15):1135-1137. 被引量:2
-
5Chunfang Luo,Runqing Zhu,Hui Wang,Yulan Lu.Expressions of cyclooxygenase-2 and matrix metalloproteinase-9 in cervical carcinoma and their clinical significance[J].The Chinese-German Journal of Clinical Oncology,2008,7(1):46-50. 被引量:3
-
6胡金川,田亚平,江朝光,谷峰,高艳红.直标法流式细胞术测定人红细胞表面CD35水平的方法学研究[J].标记免疫分析与临床,2008,15(6):396-399. 被引量:7
-
7罗春芳,王晖,洪慧莉,芦玉兰,刘铭球.COX-2和bFGF在宫颈癌中的表达及其临床意义[J].中国肿瘤临床,2011,38(7):386-390. 被引量:7
-
1杨建军,党冬梅,王明全,任常军,惠起源.肝癌患者血清p16、Runx3基因甲基化及其与临床病理参数的相关性[J].现代肿瘤医学,2013,21(5):1081-1084. 被引量:3
-
2姚群峰,宁勇,张利平,周宜开.血清p16基因甲基化联合CYFRA21-1检测在肺癌诊断中的应用[J].微循环学杂志,2006,16(1):29-31. 被引量:8
-
3陈文虎,楼正清,张毅敏.肺癌患者血清p16基因甲基化检测意义[J].浙江医学,2009,31(5):697-698.
-
4舍雅莉,张煦,李能莲,张立,王雅莉,王晓梅,胡树名,骆亚莉.胃癌组织中p16基因甲基化与其蛋白表达的相关性及临床意义[J].肿瘤,2010,30(12):1038-1041. 被引量:7
-
5黄建康,李同度,陶仪声,胡永泉,姚敏,刘德纯.膀胱移行细胞癌PCNA的表达及其意义[J].蚌埠医学院学报,2001,26(4):292-293.
-
6阚奇伟,刘伦旭,朱辉,伍贮,车国卫,诸葛雪朋.影响纤维支气管镜对肺癌检出率的因素分析[J].中国内镜杂志,2008,14(8):794-797. 被引量:1
-
7林勍,陈龙邦,唐永明,王晶.非小细胞肺癌患者血清p16基因启动子甲基化分析[J].医学研究生学报,2005,18(4):352-354. 被引量:7
-
8刘莹,王圆圆,贾文青,倪然,张辉,王静,周舫.肺癌患者血清p16、FHIT、APC基因甲基化检测[J].郑州大学学报(医学版),2017,52(1):51-54. 被引量:15
-
9杨建军,党冬梅,王明全,任常军,毕云,惠起源.原发性肝癌(HCC)TACE治疗前后p16、AFP、sVEGF的动态变化[J].现代肿瘤医学,2013,21(6):1277-1279.
-
10胡锐,田超,蒋文军,魏阳,姚文秀,龙启明,周行,王礼阳,谢华.p16基因甲基化在乳腺癌发展中的作用[J].中国普外基础与临床杂志,2011,18(5):553-554. 被引量:3